Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals

Mostra el registre complet Registre parcial de l'ítem

• dc.contributor.author Chalouni, Mathieu
• dc.contributor.author Rodríguez-Centeno, Javier
• dc.contributor.author Samri, Assia
• dc.contributor.author Blanco, Julian
• dc.contributor.author Stella-Ascariz, Natalia
• dc.contributor.author Wallet, Cedrick
• dc.contributor.author Knobel Freud, Hernando
• dc.contributor.author Zucman, David
• dc.contributor.author Alejos Ferreras, Belen
• dc.contributor.author Autran, Brigitte
• dc.contributor.author Thiebaut, Rodolphe
• dc.contributor.author Raffi, François
• dc.contributor.author Arribas, José Ramón
• dc.contributor.author NEAT001/ANRS143 Trial Study Group
• dc.date.accessioned 2021-05-10T07:35:19Z
• dc.date.available 2021-05-10T07:35:19Z
• dc.date.issued 2020
• dc.description.abstract In 31 participants who started first-line antiretroviral therapy in the NEAT 001/ANRS 143 clinical trial, we found after 96 weeks a statistically significant increase in blood telomere length (TL) of 0.04 (T/S Ratio) (p = 0.03). This increase was positively correlated with both the change in the percentage of CD4+ T-cells and with the decrease of CD38+ molecules on Central Memory CD8+ and negatively correlated with the change in the percentage of CD4+ Effector Memory cells. Increase in TL could be an expression of immune reconstitution and the associated decrease in immune activation. We acknowledge for the low statistical power due to the small sample size and the potential for false positive results due to multiple testing. Hence, further studies are needed to confirm these observations.
• dc.format.mimetype application/pdf
• dc.identifier.citation Chalouni M, Rodriguez-Centeno J, Samri A, Blanco J, Stella-Ascariz N, Wallet C, et al. Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals. PLoS One. 2020 Apr 8; 15(4): e0230772. DOI: 10.1371/journal.pone.0230772
• dc.identifier.doi http://dx.doi.org/10.1371/journal.pone.0230772
• dc.identifier.issn 1932-6203
• dc.identifier.uri http://hdl.handle.net/10230/47359
• dc.language.iso eng
• dc.publisher Public Library of Science (PLoS)
• dc.rights Copyright © 2020 Chalouni et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, https://creativecommons.org/licenses/by/4.0/ which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by/4.0/
• dc.subject.other VIH (Virus)
• dc.subject.other Immunologia
• dc.subject.other ADP-ribosyl Cyclase 1
• dc.subject.other Antiretrovirals
• dc.subject.other Limfòcits
• dc.subject.other Recomendaciones en el manejo de la pandemia por coronavirus SARS-CoV-2 (Covid-19) en pacientes con trasplante renal
• dc.title Correlation between blood telomere length and CD4+ CD8+ T-cell subsets changes 96 weeks after initiation of antiretroviral therapy in HIV-1-positive individuals
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion